Hengrui cov tshuaj tau tshaj tawm rau lub Kaum Hlis 23, hais tias: tsis ntev los no, Hengrui tshuaj tshiab tshuaj pearl ib kab kev kho mob ntawm cov qog hlwb PD-L1 qhia qhov zoo [cov qog feem pua ntawm cov qhab nia (TPS) 1 feem pua] thiab tsis nrog EGFR / ALK gene abnormal recurrent lossis metastatic non. -small cell ntsws cancer los ntawm lub teb chaws tshuaj xyuas cov tshuaj tshuaj xyuas chaw rau kev kho mob ntau yam ntawm pej xeem sau.
Raws li GLOBOCAN 2020 tsab ntawv ceeb toom, mob ntsws cancer muaj qhov thib ob ntau tshaj plaws ntawm txhua yam malignancies, tab sis cov neeg tuag yog thawj zaug, hnyav heev rau tib neeg noj qab haus huv [1]. Ntawm tag nrho cov pathologic histological hom mob ntsws cancer, NSCLC suav txog kwv yees li 85 feem pua ntawm [2]. Vim tias tsis muaj cov tsos mob tshwm sim thaum ntxov, NSCLC feem ntau muaj mob qog noj ntshav siab metastatic thaum kuaj pom, nrog rau qhov tsis zoo tag nrho. Hauv kaum xyoo dhau los, kev kho mob ntawm NSCLC tau maj mam hloov pauv los ntawm kev kho tshuaj khomob rau kev kho tus kheej raws li kev hloov pauv ntawm tus neeg tsav tsheb: kev hloov pauv ntawm tus neeg tsav tsheb tuaj yeem tau txais txiaj ntsig zoo dua los ntawm cov phiaj xwm kev kho mob, thiab tsom mus rau cov tshuaj tiv thaiv kab mob xws li PD-1 / PD-L1, ncua kev ciaj sia ntawm NSCLC siab heev. Txawm li cas los xij, tam sim no, thawj kab monotherapy rau hauv zos qib siab lossis metastatic NSCLC nrog 1 feem pua ntawm EGFR noob hloov tsis zoo thiab ALK tsis zoo rau PD-L1 TPS tseem muaj cov txiaj ntsig kho mob tsawg ntawm [3]. Yog li ntawd, raws li kev siv tshuaj tiv thaiv kab mob tam sim no, yuav ua li cas txhawm rau txhim kho qhov ua tau zoo ntawm cov tshuaj tiv thaiv kab mob, nthuav cov pej xeem tau txais txiaj ntsig los ntawm kev siv tshuaj tiv thaiv kab mob, thiab paub txog lub zeem muag ntawm dechemotherapy rau cov neeg tsav tsheb gene-negative NSCLC yog qhov tseem ceeb tsis tau txais kev kho mob.
Carreilizumab rau kev txhaj tshuaj yog humanized PD-1 monoclonal antibody ntawm nws tus kheej tsim los ntawm Hengrui Pharmaceutical thiab nrog rau cov cai ntawm kev txawj ntse. Nws tuaj yeem khi rau tib neeg PD-1 receptor thiab thaiv cov PD-1 / PD-L1 txoj hauv kev, thiab rov ua kom lub cev tiv thaiv qog noj ntshav, yog li tsim lub hauv paus ntawm kev kho mob qog noj ntshav. Txij li thaum nws pib thaum lub Tsib Hlis 2019, nws tau raug pom zoo nyob rau hauv tsib lub qog loj ntawm lub ntsws cancer, mob qog nqaij hlav hauv siab, mob qog noj ntshav, mob qog noj ntshav, mob qog noj ntshav thiab lymphoma txuas ntxiv, ntawm 2 yog thawj kab kev kho mob NSCLC, thiab nws yog ib qho ntawm cov ua thawj coj hauv tsev PD-1 cov khoom lag luam nrog cov ntaub ntawv pom zoo thiab cov qog nqaij hlav. Famitinib malate capsule yog ib qho me me molecule multi-target tyrosine kinase inhibitor ntawm nws tus kheej tsim los ntawm Hengrui. Nws muaj kev ua haujlwm inhibitory ntawm ntau yam receptor tyrosine kinases thiab belongs rau ntau lub hom phiaj los tiv thaiv angiogenic cov tshuaj.
Tam sim no, Hengrui Pharmaceutical tab tom ua ib qho randomized, qhib-daim ntawv lo, tswj, multi-center theem kev soj ntsuam kev tshawb fawb ntawm carizumab ua ke nrog famitinib malate piv nrog aborolizumab hauv thawj kab kev kho mob ntawm rov tshwm sim lossis metastatic uas tsis yog-mob qog noj ntshav nrog PD- L1 mob qog noj ntshav.
Kev txiav txim siab txog kev kho mob puas yog dab tsi?
Txhawm rau txhawb kev tshawb fawb thiab txhim kho cov tshuaj nrog cov txiaj ntsig zoo hauv kev kho mob, Lub Chaw Ntsuam Xyuas Tshuaj (CDE) tau tshaj tawm Lub Xeev Food and Drug Administration rau
